- Home
- EXEL vs BEN Comparison
EXEL vs BEN Comparison
Compare EXEL & BEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- BEN
- Stock Information
- Founded
- EXEL 1994
- BEN 1947
- Country
- EXEL United States
- BEN United States
- Employees
- EXEL N/A
- BEN N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- BEN Investment Managers
- Sector
- EXEL Health Care
- BEN Finance
- Exchange
- EXEL Nasdaq
- BEN Nasdaq
- Market Cap
- EXEL 11.1B
- BEN 12.1B
- IPO Year
- EXEL 2000
- BEN N/A
- Fundamental
- Price
- EXEL $42.52
- BEN $21.57
- Analyst Decision
- EXEL Buy
- BEN Hold
- Analyst Count
- EXEL 24
- BEN 11
- Target Price
- EXEL $44.73
- BEN $23.05
- AVG Volume (30 Days)
- EXEL 3.3M
- BEN 4.1M
- Earning Date
- EXEL 11-04-2025
- BEN 11-07-2025
- Dividend Yield
- EXEL N/A
- BEN 5.77%
- EPS Growth
- EXEL 53.55
- BEN 7.28
- EPS
- EXEL 2.38
- BEN 0.91
- Revenue
- EXEL $2,288,218,000.00
- BEN $8,770,700,000.00
- Revenue This Year
- EXEL $9.14
- BEN N/A
- Revenue Next Year
- EXEL $12.51
- BEN $5.20
- P/E Ratio
- EXEL $17.53
- BEN $24.36
- Revenue Growth
- EXEL 9.93
- BEN 3.45
- 52 Week Low
- EXEL $31.90
- BEN $16.25
- 52 Week High
- EXEL $49.62
- BEN $26.08
- Technical
- Relative Strength Index (RSI)
- EXEL 60.26
- BEN 38.34
- Support Level
- EXEL $41.23
- BEN $21.50
- Resistance Level
- EXEL $43.72
- BEN $23.13
- Average True Range (ATR)
- EXEL 1.47
- BEN 0.58
- MACD
- EXEL 0.34
- BEN -0.06
- Stochastic Oscillator
- EXEL 83.81
- BEN 2.88
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
About BEN Franklin Resources Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.